Abstract
Ceramidases are ubiquitous amidohydrolases that catalyze the cleavage of ceramides into sphingosine and fatty acids. This reaction exerts a cytoprotective role in physiological conditions, while altered ceramidase activities favour a number of human diseases. Among these diseases, several reports point to important roles of ceramidases, mainly the acid ceramidase, in the initiation and progression of cancer, and the response of tumors to radio- or chemotherapy. Multiple reports confirm the interest of acid ceramidase inhibitors as anticancer drugs, either alone or in combination with other therapies. Sphingolipid metabolism plays a role in hematological malignancies and appears as an interesting target for therapeutic intervention. Although the use of ceramidase inhibitors in chemotherapy of hematologic cancers has not been widely investigated, a number of indirect evidence suggest that inhibition of specific ceramidases could potentiate the effect of drugs in clinical use to treat hematologic malignancies and may afford strategies to combat relapses. The arsenal of ceramidase inhibitors so far available is wide and hopefully, upcoming research will assess the feasibility of this approach.
Keywords: Sphingolipids, ceramidase, cancer, enzyme inhibitor, chemotherapy, enzyme assay, ACERs, AC, NC, ER, NOE, LNCaP
Anti-Cancer Agents in Medicinal Chemistry
Title: Ceramidases in Hematological Malignancies: Senseless or Neglected Target?
Volume: 11 Issue: 9
Author(s): Gemma Fabrias, Carmen Bedia, Josefina Casas, Jose Luis Abad and Antonio Delgado
Affiliation:
Keywords: Sphingolipids, ceramidase, cancer, enzyme inhibitor, chemotherapy, enzyme assay, ACERs, AC, NC, ER, NOE, LNCaP
Abstract: Ceramidases are ubiquitous amidohydrolases that catalyze the cleavage of ceramides into sphingosine and fatty acids. This reaction exerts a cytoprotective role in physiological conditions, while altered ceramidase activities favour a number of human diseases. Among these diseases, several reports point to important roles of ceramidases, mainly the acid ceramidase, in the initiation and progression of cancer, and the response of tumors to radio- or chemotherapy. Multiple reports confirm the interest of acid ceramidase inhibitors as anticancer drugs, either alone or in combination with other therapies. Sphingolipid metabolism plays a role in hematological malignancies and appears as an interesting target for therapeutic intervention. Although the use of ceramidase inhibitors in chemotherapy of hematologic cancers has not been widely investigated, a number of indirect evidence suggest that inhibition of specific ceramidases could potentiate the effect of drugs in clinical use to treat hematologic malignancies and may afford strategies to combat relapses. The arsenal of ceramidase inhibitors so far available is wide and hopefully, upcoming research will assess the feasibility of this approach.
Export Options
About this article
Cite this article as:
Fabrias Gemma, Bedia Carmen, Casas Josefina, Luis Abad Jose and Delgado Antonio, Ceramidases in Hematological Malignancies: Senseless or Neglected Target?, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (9) . https://dx.doi.org/10.2174/187152011797655104
DOI https://dx.doi.org/10.2174/187152011797655104 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Serum N-terminal Pro-brain Natriuretic Peptide Level is Associated with the Development of Chronic Kidney Diseases in Patients with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Achievements and Limitations of Complement Inhibition by Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: The Role of Complement Component 3
Mini-Reviews in Medicinal Chemistry CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) Alternative: A Novel Approach to Improve Drug Delivery
Current Drug Targets Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology Anticancer Antifolates: Current Status and Future Directions
Current Pharmaceutical Design Vitamin D and Cancer Mortality: Systematic Review of Prospective Epidemiological Studies
Anti-Cancer Agents in Medicinal Chemistry 86Y Based PET Radiopharmaceuticals: Radiochemistry and Biological Applications
Medicinal Chemistry Legumes: A Healthy and Ecological Source of Flavonoids
Current Nutrition & Food Science Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
Current Topics in Medicinal Chemistry Hepatoblastoma: Review of Pathology, Diagnosis and Modern Treatment Strategies
Current Cancer Therapy Reviews Current Therapeutic Paradigms in Glioblastoma
Reviews on Recent Clinical Trials Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia
Current Pharmaceutical Design Combination Therapy with Arsenic Trioxide for Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine DNA Damage and Epigenetic Changes in Kidney Diseases - Focused on Transcription Factors in Podocytes
Current Hypertension Reviews Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry